Please use this identifier to cite or link to this item: https://hdl.handle.net/1/2291
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNguyen, James-
dc.contributor.authorWellard, Cameron-
dc.contributor.authorChung, Eliza-
dc.contributor.authorCheah, Chan Y-
dc.contributor.authorDickinson, Michael-
dc.contributor.authorDoo, Nicole Wong-
dc.contributor.authorKeane, Colm-
dc.contributor.authorTalaulikar, Dipti-
dc.contributor.authorBerkahn, Leanne-
dc.contributor.authorMorgan, Susan-
dc.contributor.authorHamad, Nada-
dc.contributor.authorCochrane, Tara-
dc.contributor.authorJohnston, Anna M-
dc.contributor.authorForsyth, Cecily J-
dc.contributor.authorOpat, Stephen-
dc.contributor.authorBarraclough, Allison-
dc.contributor.authorMutsando, Howard-
dc.contributor.authorRatnasingam, Sumita-
dc.contributor.authorGiri, Pratyush-
dc.contributor.authorWood, Erica M-
dc.contributor.authorMcQuilten, Zoe K-
dc.contributor.authorHawkes, Eliza A-
dc.date.accessioned2023-01-09T00:02:39Z-
dc.date.available2023-01-09T00:02:39Z-
dc.date.issued2022-12-20-
dc.identifier.citation110(4):386-395en
dc.identifier.urihttps://hdl.handle.net/1/2291-
dc.description.abstractComprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been systematically collected and described. We report real-world data of 498 eligible patients from the first 5 years of the Lymphoma and Related Diseases Registry (LaRDR), including baseline characteristics, histologic subtype, and treatment patterns in first-line therapy. Patient demographics and distribution of histopathological subtypes of cHL are similar to reported international cohorts. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was the most common therapy for both early and advanced-stage disease, and 48% of patients with the early-stage disease received radiotherapy. Treatment patterns are consistent with international guidelines. In comorbid patients ≥60 years of age with advanced-stage disease, there is greater variation in treatment. In patients with a recorded response, the objective response rate (ORR) was 96% in early-stage disease, and 88% in advanced-stage disease. Early progression-free survival data suggest Australian patients with cHL have good outcomes, similar to other international studies.en
dc.description.sponsorshipHaematologyen
dc.subjectHematologyen
dc.subjectHaematologyen
dc.subjectCanceren
dc.titleClinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registryen
dc.typeJournal Articleen
dc.identifier.doi10.1111/ejh.13915en
dc.description.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/36539351en
dc.description.affiliatesCentral Coast Local Health Districten
dc.description.affiliatesGosford Hospitalen
dc.identifier.journaltitleEuropean Journal of Haematologyen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
crisitem.author.deptHaematology-
Appears in Collections:Haematology
Show simple item record

Page view(s)

64
checked on Mar 28, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.